NeuroSense Therapeutics - חוב לטווח קצר של החברה NRSN

The monopoly potential of ALS therapy will provide NeuroSense Therapeutics (NRSN) with significant pricing power, although current short-term liabilities demonstrate balance sheet pressure due to a high burn rate and trial uncertainty. The value of 0.00 reflects the latest metric value. Cash gap risks are mitigated by transparent grant control and strict regulatory compliance by academic management, which stabilizes the company's financial position.

Developing innovative ALS therapies requires significant capital expenditures, and therefore, analyzing short-term borrowing metrics allows for an assessment of NeuroSense Therapeutics (NRSN) liquidity over a one-year horizon. This metric aggregates all obligations maturing within twelve months, demonstrating the company's ability to fund current research without compromising long-term growth or the brand's financial stability.